PDCD1 and neoplasm: Similarly, dual immune checkpoint blockade, such as targeting PD-1 in combination with CTLA-4, LAG-3, TIM-3, or TIGIT, has shown potential in restoring anti-tumor immunity, particularly in refractory settings [210,215,216,217,218].